首页> 外文期刊>BJOG: an international journal of obstetrics and gynaecology >Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
【24h】

Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study

机译:酶血清胆汁酸的酶促定量作为妊娠肝内胆汁淤积症的妇女的监测策略接受熊毒糖酸治疗:队列研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective To evaluate enzymatic total serum bile acid quantification as a monitoring strategy for women with intrahepatic cholestasis of pregnancy (ICP) treated with ursodeoxycholic acid (UDCA). Design Cohort. Setting One UK university hospital. Population 29 ICP cases treated with UDCA. Methods Serial samples were collected prospectively throughout gestation. Total serum bile acids were measured enzymatically and individual bile acids by high-performance liquid chromatography-tandem mass spectrometry. Data were log-transformed and analysed with random effects generalised least square regression. Main outcome measures The relationship between enzymatic total bile acid measurements and individual bile acid concentrations after UDCA treatment. Results In untreated women, cholic acid was the principal bile acid (51%) and UDCA concentrations were <0.5%, whereas UDCA constituted 60% (IQR 43-69) of serum bile acids following treatment and cholic acid fell to <20%. Changes in the total bile acid measurement reflected similar alterations in the concentrations of the pathologically elevated bile acids, e.g. a two-fold increase in enzymatic total bile acids is accompanied by approximately a two-fold increase in cholic acid and chenodeoxycholic acid at most UDCA doses (P < 0.001). Most of the effects of UDCA on cholic acid occur in the first week of treatment (60% relative reduction, P = 0.025, 95% CI 0.2-0.9, from 10 micromol/l (4.7-17.6) to 3.5 micromol/l (1.4-7.5). Conclusion Ursodeoxycholic acid becomes the main component of the bile acid measurement after treatment. Enzymatic total bile acid assays are good predictors of both cholic acid and chenodeoxycholic acid, the primary bile acids that are raised prior to treatment. Tweetable abstract Ursodeoxycholic acid constitutes approximately 60% of the bile acid measurement and reduces pathological cholic acid in treated women.
机译:目的评价酶总血清胆汁酸定量作为孕核酸胆酸(UDCA)处理的妊娠(ICP)肝内胆汁淤积症的监测策略。设计队列。设置一个英国大学医院。人口29例用UDCA处理的ICP病例。方法在整个妊娠中期预先收集连续样品。通过高效液相色谱 - 串联质谱法测量酶促和单个胆汁酸的总血清胆汁酸。数据被记录和分析随机效果广义最小二乘回归。主要结果测量UDCA治疗后酶促总胆汁酸测量和单个胆汁酸浓度之间的关系。结果未经处理的女性,胆酸是主要胆汁酸(51%),UDCA浓度<0.5%,而UDCA在处理后血清胆汁酸的60%(IQR 43-69),胆酸下降到<20%。总胆汁酸测量的变化反映了病于病理升高的胆汁酸的浓度的类似改变,例如,酶总胆汁酸的两倍增加伴随着大多数UDCA剂量(P <0.001)的胆酸和ChenodoOxycholic酸的大约两倍增加。 UDCA对胆酸的大部分效果发生在治疗的第一周(相对还原60%,p = 0.025,95%CI 0.2-0.9,从10μm/ L(4.7-17.6)至3.5微米/ L(1.4 -7.5)。结论核糖氧胆酸成为治疗后胆汁酸测量的主要成分。酶总胆汁酸测定是胆酸和赤铁糖胆酸的良好预测因子,治疗前饲养的初级胆汁酸。可行的抽象尿酸胆胆酸构成大约60%的胆汁酸测量并减少治疗妇女的病理胆酸。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号